GlassScriptPhysician profile
Ali S Vaziri
NPI 1710954706
$807.77
in general payments reported to CMS, 2019-2025
13 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.33 · 2021: $46.50 · 2022: $116 · 2023: $143 · 2024: $30.31 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $153.28 | 2023-2025 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $142.89 | 2022-2023 | Dupixent |
| Lilly USA, LLC | $124.13 | 2025 | Zepbound |
| Abbvie INC. | $81.64 | 2025 | |
| Qol Medical, LLC | $72.91 | 2019-2023 | Sucraid |
| Pfizer INC. | $58.51 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $46.52 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $29.87 | 2021-2023 | Ocaliva |
| Orphalan INC | $28.93 | 2025 | Cuvrior |
| Genzyme Corporation | $26.57 | 2023 | |
| Gilead Sciences, INC. | $16.68 | 2021 | |
| Celgene Corporation | $16.37 | 2021 | |
| Organon LLC | $9.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Vaziri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.